[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"FzioMed\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100561731","evaluation-of-dynavisc-in-pain-reduction-following-revision-surgery-for-persistent-or-recurrent-carpal-tunnel-syndrome-100561731",false,"NCT06593977","Evaluation of Dynavisc in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome","A Multicenter, Evaluator-Blinded, Randomized Evaluation of DYNAVISC in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome","Inclusion criteria\n\n* Signed and dated informed consent form;\n* Stated willingness to comply with all study procedures and availability for the duration of the study;\n* Aged 18-65 years of age;\n* In good general health;\n* Patients experiencing recurrence or persistence of pain in the ipsilateral hand after previous carpal tunnel release for surgical treatment of primary carpal tunnel syndrome;\n* All of the following physical examination tests must be performed; at least one must be positive:\n\n  1. Physical examination demonstrates positive Phalen test;\n  2. Physical examination demonstrates positive Tinel's test;\n  3. Physical examination demonstrates positive monofilament test;\n* ENMG demonstrates median nerve velocity and deviation consistent with the diagnosis of carpal tunnel syndrome.\n\nExclusion criteria\n\n* Inability to understand the clinical trial and\u002For sign the Informed Consent;\n* Unable or unwilling to attend all of the study prescribed visits and data collection forms;\n* Active infection requiring medication;\n* Drug requiring diabetes mellitus;\n* Collagenopathies;\n* Hypothyroidism requiring medication;\n* Rheumatoid arthritis requiring medication;\n* Autoimmune disease requiring medication;\n* Cervical nerve compression;\n* Hematopoietic disorders;\n* Lacertus fibrosis;\n* Psychiatric disorder requiring medical treatment;\n* Subject of workers compensation claim;\n* History of cancer, except for basal or squamous cell skin cancer;\n* Known allergic reactions to components of DYNAVISC;\n* Actively participating in another clinical trial.","ALL","18 Years","65 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The trial will evaluate the efficacy of DYNAVISC in subjects with a diagnosis of persistent or recurrent carpal tunnel syndrome. This is a prospective, multicenter, randomized, evaluator-blinded clinical trial. Results will be stratified based on the method used for median nerve coverage: Group 1 (standard of care surgery followed by DYNAVISC surrounding the median nerve, n=25 participants), Group 2 (standard of care surgery followed by coverage of the median nerve with a hypothenar fat pad flap, n=25",[27],"Carpal Tunnel Syndrome (CTS)",[29,30],"carpal tunnel","revision","RECRUITING","2026-03-31",{"date":34,"type":35},"2026-04-06","ACTUAL",{"date":37,"type":21},"2026-03-26",{"date":39,"type":21},"2027-10",{"name":41,"class":42},"FzioMed","INDUSTRY",4,""]